PRLD Prelude Therapeutics Inc: institutional ownership and insider trading
82 funds reported holding $270M of Prelude Therapeutics Inc in their latest 13F filings; in Q2 2026 funds net bought $102M, with 34 new positions and 11 funds selling out; over the last 12 months insiders bought $25.0M and sold $0 on the open market.
Famous investors holding PRLD
- Two Sigma (Two Sigma Investments): $5.29M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $4.50M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.50M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $373K, 0.0% of the portfolio
Largest institutional holders of PRLD
- ORBIMED ADVISORS LLC — $73.2M
- BAKER BROS. ADVISORS LP — $54.0M
- RA CAPITAL MANAGEMENT, L.P. — $34.5M
- Soleus Capital Management, L.P. — $18.0M
- Kynam Capital Management, LP — $12.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $10.7M
- BlackRock, Inc. (BLK) — $9.58M
- SPHERA FUNDS MANAGEMENT LTD. — $5.44M
- TWO SIGMA INVESTMENTS, LP — $5.29M
- ADAR1 Capital Management, LLC — $4.80M
Recent PRLD insider trades
- Apr 21, 2026: Bonita David P bought 2,815,315 shares ($12.5M)
- Apr 21, 2026: Orbimed Advisors Llc bought 2,815,315 shares ($12.5M)
- Mar 25, 2025: Vaddi Krishna bought 675,000 shares ($466K)
- Mar 25, 2025: Combs Andrew bought 100,000 shares ($69.0K)
5%+ owners
- ORBIMED ADVISORS LLC: 16.0% (Schedule 13D/A, filed Apr 23, 2026)
- Baker Bros. Advisors LP: 15.5% (Schedule 13D/A, filed Apr 22, 2026)
- RA Capital Management, L.P.: 9.9% (Schedule 13G, filed Apr 28, 2026)
- Soleus Capital Management, L.P.: 5.2% (Schedule 13G, filed Jul 8, 2026)